 |
市場調查報告書
商品編碼
1477243
糖尿病腎病變市場，依藥物類別、依給藥途徑、依配銷通路、依地理位置Diabetic Kidney Disease Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
預計2024年全球糖尿病腎病變市場價值為30.3億美元，預計到2031年將達42.1億美元，2024年至2031年年複合成長率(CAGR)為4.8%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2023年 | 2024 年市場規模： | 30.3 億美元 |
| 歷史數據： | 2019年至2023年 | 預測期： | 2024年至2031年 |
| 預測 2024 年至 2031 年複合年成長率： | 4.80% | 2031 年價值預測： | 42.1 億美元 |
圖 1. 2024 年糖尿病腎病變市場佔有率 (%)（依地區）
糖尿病腎病變（DKD）是一種因長期糖尿病而導致腎臟受損的疾病。隨著時間的推移，糖尿病引起的高血糖會損害腎臟的小血管以及腎臟內的過濾單位（腎小球）。如果不能有效控制，腎小球損傷會降低腎功能，並可能導致腎衰竭。隨著全球糖尿病盛行率的不斷上升，糖尿病腎病變的治療市場預計在不久的將來將穩定成長。
市場動態：
由於全球糖尿病和肥胖症盛行率不斷上升，全球糖尿病腎病變市場正在顯著成長。推動市場成長的一些關鍵促進因素包括更容易患慢性腎病的老年人口的增加、對 DKD 早期診斷和治療的認知不斷提高，以及美國 FDA 擴大批准治療 DKD 的新藥。然而，腎衰竭治療相關的高成本以及低收入地區缺乏疾病意識等因素可能會阻礙市場成長。持續不斷的研發工作旨在開發更有效且安全性更高的藥物，為市場參與者提供了利潤豐厚的機會。預計世界各國政府在腎臟保健方面的醫療支出增加將在預測期內創造積極的商業環境。
研究的主要特點：
- 該報告對全球糖尿病腎病變市場進行了深入分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
- 它闡明了不同區隔市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
- 這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
- 它根據以下參數描述了全球糖尿病腎病變市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
- 該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 全球糖尿病腎病變市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
- 利害關係人可以透過用於分析全球糖尿病腎病變市場的各種策略矩陣輕鬆做出決策。
目錄
第1章：研究目標與假設
- 研究目標
- 假設
- 縮寫
第 2 章：市場範圍
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map (COM)
第 3 章：市場動態、法規與趨勢分析
- 市場動態
- 促進要素
- 限制
- 市場機會
- 影響分析
- 市場走向
- 最近的發展
- 收購和合作場景
- 技術概覽
- 監管場景
- 定價分析
- PEST分析
第 4 章：全球糖尿病腎病變市場 - 冠狀病毒 (COVID-19) 大流行的影響
- 整體影響
- 政府舉措
- COVID-19 對市場的影響
第 5 章：2019 - 2031 年全球糖尿病腎病變市場（依藥物類別）（十億美元）
- 概述
- 血管張力素受體阻斷劑 (ARB)
- 鈣通道阻斷劑
- 抗氧化發炎調節劑
- 血管緊張素轉換酶 (ACE) 抑制劑
- 其他
第 6 章：2019 - 2031 年全球糖尿病腎病變市場（依給藥途徑）（十億美元）
- 概述
- 口服
- 注射用
第 7 章：全球糖尿病腎病變市場，依配銷通路，2019 - 2031 年（十億美元）
- 概述
- 醫院藥房
- 零售藥局
- 網路藥局
第 8 章：2019 - 2031 年全球糖尿病腎病變市場（依地區）（十億美元）
- 介紹
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 歐洲其他地區
- 亞太地區
- 中國
- 印度
- 日本
- 東協
- 澳洲
- 韓國
- 亞太地區其他地區
- 中東
- 海灣合作理事會
- 以色列
- 中東其他地區
- 非洲
- 北非
- 中非
- 南非
第 9 章：競爭格局
- 公司簡介
- AstraZeneca
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- Bristol Myers Squibb
- GSK
- Novo Nordisk
- Eli Lilly and Company
- Merck & Co.
- Sanofi
- AbbVie
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- Lupin
- Aurobindo Pharma
- Takeda Pharmaceutical Company Limited
- Biogen
- Vertex Pharmaceuticals Incorporated
第 10 章：分析師觀點
- 命運之輪
- 分析師觀點
- 連貫的機會圖
第 11 章：參考文獻與研究方法
- 參考
- 研究方法論
簡介目錄
Product Code: CMI6852
Global diabetic kidney disease market is estimated to be valued at USD 3.03 Bn in 2024 and is expected to reach USD 4.21 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 3.03 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 4.80% | 2031 Value Projection: | US$ 4.21 Bn |
Figure 1. Diabetic Kidney Disease Market Share (%), By Region, 2024
Diabetic kidney disease (DKD) is a condition in which the kidneys are damaged due to long-standing diabetes. Over time, high blood sugar from diabetes can damage both the small blood vessels in the kidneys as well as the filtering units (glomeruli) within the kidneys. Damage to the glomeruli can reduce kidney function and may lead to kidney failure, if not controlled effectively. With increasing prevalence of diabetes globally, the market for treatments of diabetic kidney disease is projected to grow steadily in the near future.
Market Dynamics:
Global diabetic kidney disease market is witnessing significant growth due to rising prevalence of diabetes and obesity worldwide. Some of the key drivers fueling the market growth include growing geriatric population who are more susceptible to chronic kidney diseases, rising awareness about early diagnosis and treatment of DKD, and increasing U.S. FDA approvals of novel drugs to treat DKD. However, factors such as high costs associated with kidney failure treatments and lack of diseases awareness in low-income regions can hamper the market growth. Ongoing R&D efforts to develop more efficacious drugs with improved safety profiles provide lucrative opportunities for market players. Increasing health expenditures of governments worldwide on kidney care is anticipated to create a positive business environment during the forecast period.
Key Features of the Study:
- This report provides in-depth analysis of the global diabetic kidney disease market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global diabetic kidney disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb, GSK, Novo Nordisk, Eli Lilly and Company, Merck & Co., Sanofi, AbbVie, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Lupin, Aurobindo Pharma, Takeda Pharmaceutical Company Limited, Biogen, and Vertex Pharmaceuticals Incorporated.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global diabetic kidney disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic kidney disease market.
Detailed Segmentation-
- Drug Class:
- Angiotensin Receptor Blockers (ARBs)
- Calcium Channel Blockers
- Antioxidant Inflammation Modulator
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Others
- Route of Administration:
- Oral
- Parenteral
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- AstraZeneca
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- Bristol Myers Squibb
- GSK
- Novo Nordisk
- Eli Lilly and Company
- Merck & Co.
- Sanofi
- AbbVie
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- Lupin
- Aurobindo Pharma
- Takeda Pharmaceutical Company Limited
- Biogen
- Vertex Pharmaceuticals Incorporated
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Diabetic Kidney Disease Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Diabetic Kidney Disease Market, By Drug Class, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Angiotensin Receptor Blockers (ARBs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Calcium Channel Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Antioxidant Inflammation Modulator
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
6. Global Diabetic Kidney Disease Market, By Route of Administration, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
7. Global Diabetic Kidney Disease Market, By Distribution Channel, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
8. Global Diabetic Kidney Disease Market, By Region, 2019 - 2031, (USD BN)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- Bristol Myers Squibb
- GSK
- Novo Nordisk
- Eli Lilly and Company
- Merck & Co.
- Sanofi
- AbbVie
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- Lupin
- Aurobindo Pharma
- Takeda Pharmaceutical Company Limited
- Biogen
- Vertex Pharmaceuticals Incorporated
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
